The effect of Q10 supplementation in treatment of women with polycystic ovary syndrome
Phase 3
- Conditions
- Polycystic ovary syndrome.Polycystic ovarian syndrome
- Registration Number
- IRCT20170513033941N52
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Patients with polycystic ovary syndrome candidates for IVF
Individuals aged 18 to 40 years
Exclusion Criteria
Individuals with neoplastic disorders
cardiovascular diseases
malabsorptive disorders
current or previous (within the last 6 months) use of hormonal; antidiabetic and anti-obesity medications.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Insulin resistance. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Insulin. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.
- Secondary Outcome Measures
Name Time Method Total cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Expressed levels of GLUT-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of LDL-R gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.